Telix Pharmaceuticals Limited (ASX:TLX)
Australia · Delayed Price · Currency is AUD 18.33
+0.23 (1.27%)
Aug 22, 2025, 4:13 PM AEST
Telix Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 1,013 | 783.21 | 502.55 | 160.1 | 7.6 | 5.21 | Upgrade | |
Revenue Growth (YoY) | 58.10% | 55.85% | 213.90% | 2007.64% | 45.71% | 49.58% | Upgrade |
Cost of Revenue | 466.67 | 299.26 | 198.03 | 65.17 | 2.55 | 2.02 | Upgrade |
Gross Profit | 546.48 | 483.95 | 304.52 | 94.93 | 5.05 | 3.19 | Upgrade |
Selling, General & Admin | 257.33 | 207.13 | 124.29 | 87.1 | 46.99 | 24.48 | Upgrade |
Research & Development | 234.52 | 194.64 | 128.54 | 81.01 | 34.14 | 23.09 | Upgrade |
Other Operating Expenses | 11.78 | 0.29 | -0.19 | 0.93 | - | - | Upgrade |
Operating Expenses | 503.62 | 402.05 | 252.63 | 169.03 | 86.3 | 52.44 | Upgrade |
Operating Income | 42.86 | 81.9 | 51.89 | -74.11 | -81.25 | -49.25 | Upgrade |
Interest Expense | -16.22 | -7.25 | -0.78 | -0.32 | -0.16 | -0.19 | Upgrade |
Interest & Investment Income | 15.01 | 10.86 | 1.02 | 0 | - | 0.07 | Upgrade |
Currency Exchange Gain (Loss) | 20.44 | 18.71 | -0.97 | -1.12 | 1.7 | -3.94 | Upgrade |
Other Non Operating Income (Expenses) | -29.84 | -29.69 | -12.99 | -6.37 | 14.1 | 12.11 | Upgrade |
EBT Excluding Unusual Items | 32.24 | 74.53 | 38.17 | -81.92 | -65.61 | -41.21 | Upgrade |
Merger & Restructuring Charges | -8.18 | -8.18 | - | - | - | - | Upgrade |
Asset Writedown | 0.77 | 0.77 | -0.8 | - | - | - | Upgrade |
Other Unusual Items | -11.04 | -11.06 | -34.28 | -16.71 | -14.86 | -6.73 | Upgrade |
Pretax Income | 13.79 | 56.06 | 3.09 | -98.62 | -80.47 | -47.94 | Upgrade |
Income Tax Expense | -2.75 | 6.14 | -2.12 | 5.46 | 0.05 | -3.05 | Upgrade |
Net Income | 16.54 | 49.92 | 5.21 | -104.08 | -80.51 | -44.89 | Upgrade |
Net Income to Common | 16.54 | 49.92 | 5.21 | -104.08 | -80.51 | -44.89 | Upgrade |
Net Income Growth | -66.17% | 857.95% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 254 | 331 | 319 | 311 | 282 | 257 | Upgrade |
Shares Outstanding (Diluted) | 260 | 345 | 324 | 311 | 282 | 257 | Upgrade |
Shares Change (YoY) | -37.99% | 6.64% | 4.21% | 10.08% | 9.69% | 10.21% | Upgrade |
EPS (Basic) | 0.07 | 0.15 | 0.02 | -0.34 | -0.29 | -0.17 | Upgrade |
EPS (Diluted) | 0.07 | 0.14 | 0.02 | -0.34 | -0.29 | -0.17 | Upgrade |
EPS Growth | -44.27% | 798.14% | - | - | - | - | Upgrade |
Free Cash Flow | 14.7 | 28.71 | 14.21 | -71.01 | -60.67 | 1.71 | Upgrade |
Free Cash Flow Per Share | 0.06 | 0.08 | 0.04 | -0.23 | -0.21 | 0.01 | Upgrade |
Gross Margin | 53.94% | 61.79% | 60.60% | 59.29% | 66.46% | 61.17% | Upgrade |
Operating Margin | 4.23% | 10.46% | 10.32% | -46.29% | -1069.60% | -944.81% | Upgrade |
Profit Margin | 1.63% | 6.37% | 1.04% | -65.01% | -1059.90% | -861.06% | Upgrade |
Free Cash Flow Margin | 1.45% | 3.67% | 2.83% | -44.35% | -798.67% | 32.84% | Upgrade |
EBITDA | 55.53 | 87.58 | 57.17 | -69.59 | -76.73 | -44.94 | Upgrade |
EBITDA Margin | 5.48% | 11.18% | 11.38% | -43.47% | - | - | Upgrade |
D&A For EBITDA | 12.67 | 5.69 | 5.29 | 4.52 | 4.52 | 4.31 | Upgrade |
EBIT | 42.86 | 81.9 | 51.89 | -74.11 | -81.25 | -49.25 | Upgrade |
EBIT Margin | 4.23% | 10.46% | 10.32% | -46.29% | - | - | Upgrade |
Effective Tax Rate | - | 10.95% | - | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.